Antiviral treatment of hepatitis B virus-transgenic mice by a marine organism, Styela plicata

Table 1 Changes of HBsAg titers (mean ± SD)

Treatment group	OD values
	0 wk	4 wk	8 wk	12 wk	16 wk
Group 1 normal diet recipients (n = 9)	1.61 ± 0.01	1.61 ± 0.01	1.62 ± 0.02	1.62 ± 0.01	1.60 ± 0.02
Group 2 lamivudine recipients (n = 9)	1.59 ± 0.03	1.00 ± 0.21a,d	0.92 ± 0.15b,d	0.76 ± 0.08b,d	1.29 ± 0.11a,d
Group 3 Sp recipients (n = 9)	1.61 ± 0.02	1.32 ± 0.08a	1.01 ± 0.16b,d	0.82 ± 0.07b,d	1.05 ± 0.05b,d

^aP < 0.05, ^bP < 0.01 compared with T0 in one group; ^dP < 0.01 compared with group 1.

Table 2 Anti-HBV DNA production (mean ± SD)

Treatment group	Serum HBV DNA (copies/mL)
	0 wk	4 wk	8 wk	12 wk	16 wk
Group 1 normal diet recipients (n = 9)	1.35E05 ± 3.64E04	1.34 E05 ± 3.20 E04	1.53 E05 ± 3.10 E04	1.30 E05 ± 2.43 E04	2.59 E05 ± 9.37 E04
Group 2 lamivudine recipients (n = 9)	1.20 E05 ± 2.54 E04	5.52 E04 ± 1.63 E04b	2.48 E04 ± 8.12E03b,d	1.34 E04 ± 4.48 E03b,d	1.12 E05 ± 2.70 E04
Group 3 Sp recipients (n = 9)	1.73 E05 ± 4.69 E04	8.39 E04 ± 4.32 E04	4.07 E04 ± 1.63 E04a,d	1.19 E04 ± 7.53 E03b,d	1.91 E05 ± 6.87 E04

^aP < 0.05, ^bP < 0.01 compared with T0 in one group; ^dP < 0.01 compared with group 1.

Table 3 Data are expressed as mean ± SD

Treatment group	IL-2 (ng/L)			IL-6 (ng/L)
	0 wk	4 wk	8 wk	0 wk	4 wk	8 wk
Group 1 normal diet recipients (n = 9)	2.13 ± 0.23	2.33 ± 0.26	2.48 ± 0.17	63.59 ± 1.82	65.40 ± 10.3	60.84 ± 4.21
Group 3 Sp recipients (n = 9)	2.41 ± 0.38	7.91 ± 1.09b,-d	10.56 ± 0.78b,d	63.62 ± 6.31	61.80 ± 4.58	54.52 ± 6.22

^bP< 0.01 vs T0 in one group; ^dP < 0.01 vs group 1.

Table 4 Inflammatory degree and degeneration degree of hepatocytes in HBV-Tg liver after 10 wk of treatment (mean ± SD, n = 5)

	0 wk	10 wk
Degeneration degree of hepatocytes	8.00 ± 0.63	5.60 ± 0.68b
Inflammation degree of hepatocytes	5.20 ± 0.37	4.00 ± 0.32a

^aP < 0.05, ^bP < 0.01 vs T0 in one group.